Soluble Guanylate Cyclase Modulators in Heart Failure

Mitrović, Veselin; Lehinant, Stefan

doi:10.5772/37167

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Production of NO is known to be reduced in several cardiovascular diseases including hypertension and heart failure. It has been demonstrated that sGC activators could have a beneficial effect in cardiac hypertrophy associated with cardiovascular disease and heart failure . A recent study by Fraccarollo et al.…”

Section: Discussionmentioning

confidence: 99%

Effect of different drug classes on reverse remodeling of intramural coronary arterioles in the spontaneously hypertensive rat

Mancini¹,

Scavone

Sartório

et al. 2017

Microcirculation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of different drug classes on reverse remodeling of intramural coronary arterioles in the spontaneously hypertensive rat

Mancini¹,

Scavone

Sartório

et al. 2017

Microcirculation

View full text Add to dashboard Cite

show abstract

“…Die Guanylatzyklase stimuliert die Bildung des Second Messengers cGMP („cyclic guanosine monophosphate“), welcher unter anderem eine verstärkte Vasorelaxation, eine verminderte Proliferation glatter Muskelzellen sowie eine Abnahme der Leukozytenrekrutierung und der Thrombozytenaggregation bewirkt [ 55 ]. Bei Patienten mit chronischer Herzinsuffizienz kann jedoch eine Oxidation der Guanylatzyklase einsetzen, wodurch diese nicht mehr endogen aktiviert werden kann und es zu einer Abnahme der cGMP-Spiegel kommt [ 56 ]. Mithilfe löslicher Guanylatzyklaseaktivatoren bzw.…”

Section: Behandlung Mit Guanylatzyklasemodulatoren Bei Chronischer Herzinsuffizienzunclassified

Neues zur Diagnostik und Therapie der Herzinsuffizienz

Wintrich

Berger

Bewarder

et al. 2021

Herz

View full text Add to dashboard Cite

ZusammenfassungInzidenz und Prävalenz der Herzinsuffizienz steigen weltweit. Trotz zahlreicher wissenschaftlicher und klinischer Innovationen ist sie weiterhin mit einer hohen Morbidität und Mortalität behaftet, sodass eine leitliniengerechte Diagnostik und Therapie von entscheidender Bedeutung sind. Die kardiale Dekompensation zählt zu den häufigsten Aufnahmegründen in deutschen Krankenhäusern. Somit stellt die Behandlung herzinsuffizienter Patienten eine erhebliche Herausforderung für das deutsche Gesundheitssystem dar. Dieser Artikel fasst die neuesten wissenschaftlichen Erkenntnisse zur akuten und chronischen Herzinsuffizienz der Jahre 2018 bis 2020 zusammen.

show abstract

“…Myocardial and endothelial dysfunctions are involved in the development and progression of HF and dysregulation of several signalling pathways, including the nitric oxide (NO)–soluble guanylyl cyclase (sGC)–cyclic guanosine monophosphate (cGMP) signalling pathway (NO‐sGC‐cGMP), contributes to these processes (Stasch et al, 2011). NO is produced by the endothelial NO synthase (eNOS) and acts as an important signalling molecule: In vascular smooth muscle cells (SMC), NO activates sGC that catalyses the synthesis of the second messenger cGMP thus regulating various physiological processes and tissue‐protective effects, including smooth muscle relaxation, inhibition of inflammation, SMC proliferation and platelet activation (Mitrovic et al, 2011). In HF, reactive oxygen species (ROS) and inflammatory mediators reduce NO bioavailability (Umar & van der Laarse, 2010).…”

Section: Introductionmentioning

confidence: 99%

Riociguat attenuates the changes in left ventricular proteome and microRNA profile after experimental aortic stenosis in mice

Benkner

Rüdebusch

Nath

et al. 2022

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose Development and progression of heart failure involve endothelial and myocardial dysfunction as well as a dysregulation of the NO‐sGC‐cGMP signalling pathway. Recently, we reported that the sGC stimulator riociguat has beneficial effects on cardiac remodelling and progression of heart failure in response to chronic pressure overload. Here, we examined if these beneficial effects of riociguat were also reflected in alterations of the myocardial proteome and microRNA profiles. Experimental Approach Male C57BL/6N mice underwent transverse aortic constriction (TAC) and sham‐operated mice served as controls. TAC and sham animals were randomised and treated with either riociguat or vehicle for 5 weeks, starting 3 weeks after surgery, when cardiac hypertrophy was established. Afterwards, we performed mass spectrometric proteome analyses and microRNA sequencing of proteins and RNAs, respectively, isolated from left ventricles (LVs). Key Results TAC‐induced changes of the LV proteome were significantly reduced by treatment with riociguat. Bioinformatics analyses revealed that riociguat improved TAC‐induced cardiovascular disease‐related pathways, metabolism and energy production, for example, reversed alterations in the levels of myosin heavy chain 7, cardiac phospholamban and ankyrin repeat domain‐containing protein 1. Riociguat also attenuated TAC‐induced changes of microRNA levels in the LV. Conclusion and Implications The sGC stimulator riociguat exerted beneficial effects on cardiac structure and function during pressure overload, which was accompanied by a reversal of TAC‐induced changes of the cardiac proteome and microRNA profile. Our data support the potential of riociguat as a novel therapeutic agent for heart failure.

show abstract

Soluble Guanylate Cyclase Modulators in Heart Failure

Cited by 4 publications

References 6 publications

Effect of different drug classes on reverse remodeling of intramural coronary arterioles in the spontaneously hypertensive rat

Effect of different drug classes on reverse remodeling of intramural coronary arterioles in the spontaneously hypertensive rat

Neues zur Diagnostik und Therapie der Herzinsuffizienz

Riociguat attenuates the changes in left ventricular proteome and microRNA profile after experimental aortic stenosis in mice

Contact Info

Product

Resources

About